IBD drugs Flashcards

(29 cards)

1
Q

what are the 5-ASA drugs and suffix to look for? and what disease are they used for

A

Sulfasalazine*
Mesalamine
Olsalazine*
Balsalazide*

“sala”

Ulcerative Colitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the Janus Kinase Inhibitor and what disease is it used for

A

Tofacitinib

Ulcerative Colitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the 3 TNF-a Inhibitors and what disease is it used for

A

Adalimumab
Golimumab
Infliximab

Ulcerative Colitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the one a-4 Integrin inhibitors and what disease are they used for

A

Vedolizumab

used for Ulcerative Colitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are first line therapy drugs that are not covered in this lecture that are used for both Ulcerative Colitis and Crohns disease

A

Steroids, Immune Modulators, and even antibiotics also utilized as first-line therapy but not officially indicated, and covered elsewhere in the Curriculum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the IL-12/23 inhibitors and what disease are they used for

A

Ustekinumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what TNF-a Inhibitors are used for Crohns disease

A

Adalimumab
Certolizumab
Infliximab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what are the 2 a-4 integrin inhibitors used in Crohns disease

A

Natalizumab

Vedolizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the 5-ASA agents mechanism of action

A

Inhibition of Prostoglandin and Leukotriene production via the arachidonic acid pathway

inhibits both Cyclooxygenase and Lipoxygenase

Reduction in PMN & macrophage chemotaxis
May also inhibit the activation of NFκB(nuclear factor kappa-light-chain-enhancer of activated B cells)
–Regulates transcription of genes for pro-inflammatory proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

when are all 5-ASA compounds contraindicated and when is Sulfasalazine contraindicated

A

All 5-ASA compounds contraindicated in ASA-allergic patients

•Sulfasalazine contraindicated in sulfonamide-allergic patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

how does administration of 5-ASA effect the extent of the disease

A

Oral:Varies by agent; may be released in the distal/terminal ileum, colon, or throughout GI tract

Rectal Enemas:
May reach the splenic flexure
Do not frequently concentrate in the rectum

Rectal Suppositories:
Reach the upper rectum (15-20 cm beyond the anal verge)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what are 5-ASA agents indications and what are the two exceptions

A

Indications (Active & Maintenance):
•Mild-to-Moderate U.C.

Except Olsalazine (only for maintenance of remission)

Except Balsalazide (only for active disease)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Mechanism of action of TNF-a Inhibitors?

A

Binds to an neutralizes membrane-associated and soluble human TNF-α-mediated pro-inflammatory cell signaling, ultimately blocking leukocyte migration to site of inflammation:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is the only TNF-a inhibitor that can be given IV for IBD

A

Infliximab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are side effects of TNF-a inhibitors?

A

Infections make sure to test for TB pre therapy since can activate from latent phase especially Adalimumab

can cause Liver toxicity

can cause Dermatologic-related (EM, SJS, TEN)
Malignancies (various)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

when are TNF-a inhibitors used and what are their indications

A

Used after inadequate response to conventional or immunosuppressant therapy

used for active and maintenance

17
Q

Mechanism of action of a-4 integrin inhibitors

A

Limits Integrin’s-associated cell adhesion and subsequent trans-endothelial migration of leukocytes to cite of inflammation

18
Q

Side effects of a-4 Integrin inhibitors and how is this monitored

A
Infections
PML (assoc. w/ John Cunningham Virus (JCV)) –3 Risk Factors for PML:
–treatment >2 years
–prior immunosuppressant treatment
–anti-JC virus (JCV) antibodies

only has been seen in natalizumab

MRI and CSF analysis

19
Q

what are the Indications of A-4 integrin inhibitors and when is the recommended use

A

All α-4 Integrininhibitors recommended for use after inadequate response to conventional or TNF-α therapy

Natalizumab
Moderate-to-Severe C.D.
not recommended in combination with immunosuppressant’s; including TNF-α agents

•Vedolizumab
Moderate-to-Severe C.D. & U.C.

20
Q

how are a-4 integrin inhibitors dosed?

A

IV every 4 or 8 hours

21
Q

Mechanism of action for IL-12/23 inhibitors

A

Bind to P40-subunit of IL-12 & IL-23 blocking activation and differentiation of naïve T cells and activation of NK cells

thereby inhibiting production of pro-inflammatory cytokines; INFg(Th1), TNF-α, IL-17 (Th17) & IL-21, among others…

22
Q

what are side effects of IL-12/23 inhibitors

A

Infections therefore must do a TB test pre therapy

23
Q

what are the indications of IL-12/23 inhibitors and when should they be used

A

Indications (Active & Maintenance):

Moderate-to-Severe U.C. & C.D

used for For patients intolerant or inadequate response (resistant) to conventional, immune modulators, steroids or TNF-α therapy

24
Q

what is the dosing of Ustekinumab

A

SQ every 8 weeks (after single IV infusion for induction)

25
Mechanism of action of JAK inhibitors
Bind to and inhibit free-floating and bound JAK-1 & JAK-3 (lesser extent to JAK-2) thereby ultimately inhibiting gene transcription & more cytokine release
26
what are the side effects of JAK inhibitors
Lymphopenia/Lymphocytosis Neutropenia/Anemia Increases in LDL & HDL (minimal ratio change) Rare: Increased risk of malignancies/serious infections –from R.A. indication-data
27
Indications and dosing of Tofacitinib?
Indications (Active & Maintenance): Moderate-to-Severe U.C. •Dosing Tofacitinib(Xeljanz) Administered PO BID
28
what is the recommendation of use of Biologic therapies and potent immunosuppressants with JAK inhibitors
Not recommended
29
What are the indications and dosing for steroid agents
Indications: Acute and/or Severe U.C. & C.D. uncontrolled by other conventional medications Not for maintenance of remission unless absolutely required (steroid-dependent) •Dosing: Use the lowest dose for shortest duration possible